Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 Plus Nab-Paclitaxel in First-line Advanced/Metastatic TNBC
NCT06419621Phase 3Active, not recruiting
- Sponsor
- Biotheus
- Start
- Jun 2024
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing PM8002 Plus Nab-Paclitaxel with Placebo Plus Nab-Paclitaxel (2 arms). Primary endpoints: Progression-Free Survival assessed by Blinded Independent Review Committee (BIRC) at 37 months and Overall Survival at 37 months. Started Jun 2024; status: active, not recruiting.
02
Drugs
pumitamig
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06419621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06419621.